DIA's Impact on the Clinical Research Industry
In the fifth and final part of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA touches on how the organization continues to break down silos in clinical research and provide a medium for collaboration.
ACT: What kind of impact do you hope DIA and its conferences have within the clinical trials industry?
Pierce: DIA really strives to be a connector that brings the right stakeholders together to have conversations that aren't going to happen elsewhere or things. There are so many things that happen in a silo in this industry. We believe strongly that it's only through cooperation and collaboration, learning from mistakes of others, tapping into their successes and building on top of them. We believe that that's the only way this industry is going to continue to really accelerate at the rate that patients need it to accelerate, and we have to be willing to have those conversations. I think DIA is the hub for bringing those groups together. We provide this neutral platform, where everybody's voice is elevated, and everybody's voice is integrated into that conversation. I think that's just a an incredibly important element of advancing innovation, so that's really what we're striving to be at the middle of and make sure that we're the party that continues to be that integrator of knowledge.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
